Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

45 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II Study With Epirubicin, Cisplatin, and Infusional Fluorouracil Followed by Weekly Paclitaxel With Metronomic Cyclophosphamide as a Preoperative Treatment of Triple-Negative Breast Cancer.
Cancello G, Bagnardi V, Sangalli C, Montagna E, Dellapasqua S, Sporchia A, Iorfida M, Viale G, Barberis M, Veronesi P, Luini A, Intra M, Goldhirsch A, Colleoni M. Cancello G, et al. Clin Breast Cancer. 2015 Aug;15(4):259-65. doi: 10.1016/j.clbc.2015.03.002. Epub 2015 Mar 18. Clin Breast Cancer. 2015. PMID: 25933934 Clinical Trial.
Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancer.
Cancello G, Maisonneuve P, Rotmensz N, Viale G, Mastropasqua MG, Pruneri G, Veronesi P, Torrisi R, Montagna E, Luini A, Intra M, Gentilini O, Ghisini R, Goldhirsch A, Colleoni M. Cancello G, et al. Ann Oncol. 2010 Oct;21(10):1974-1981. doi: 10.1093/annonc/mdq072. Epub 2010 Mar 23. Ann Oncol. 2010. PMID: 20332136 Free article.
Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes.
Cancello G, Maisonneuve P, Rotmensz N, Viale G, Mastropasqua MG, Pruneri G, Montagna E, Dellapasqua S, Iorfida M, Cardillo A, Veronesi P, Luini A, Intra M, Gentilini O, Scarano E, Goldhirsch A, Colleoni M. Cancello G, et al. Breast Cancer Res Treat. 2011 Jun;127(3):713-20. doi: 10.1007/s10549-011-1465-7. Epub 2011 Mar 31. Breast Cancer Res Treat. 2011. PMID: 21452022
Changes in PgR and Ki-67 in residual tumour and outcome of breast cancer patients treated with neoadjuvant chemotherapy.
Montagna E, Bagnardi V, Viale G, Rotmensz N, Sporchia A, Cancello G, Balduzzi A, Galimberti V, Veronesi P, Luini A, Mastropasqua MG, Casadio C, Sangalli C, Goldhirsch A, Colleoni M. Montagna E, et al. Among authors: cancello g. Ann Oncol. 2015 Feb;26(2):307-13. doi: 10.1093/annonc/mdu528. Epub 2014 Nov 19. Ann Oncol. 2015. PMID: 25411418 Free article.
Evaluation of endocrine therapy and patients preferences in early breast cancer: results of Elena study.
Montagna E, Pagan E, Bagnardi V, Colleoni M, Cancello G, Munzone E, Dellapasqua S, Bianco N, Campennì G, Iorfida M, Mazza M, De Maio A, Veronesi P, Sangalli C, Scateni B, Pettini G, Pravettoni G, Mazzocco K, Galimberti V. Montagna E, et al. Among authors: cancello g. Breast Cancer Res Treat. 2020 Dec;184(3):783-795. doi: 10.1007/s10549-020-05900-2. Epub 2020 Sep 14. Breast Cancer Res Treat. 2020. PMID: 32929568
Pathological complete response after preoperative systemic therapy and outcome: relevance of clinical and biologic baseline features.
Montagna E, Bagnardi V, Rotmensz N, Viale G, Pruneri G, Veronesi P, Cancello G, Balduzzi A, Dellapasqua S, Cardillo A, Luini A, Zurrida S, Gentilini O, Mastropasqua MG, Bottiglieri L, Iorfida M, Goldhirsch A, Colleoni M. Montagna E, et al. Among authors: cancello g. Breast Cancer Res Treat. 2010 Dec;124(3):689-99. doi: 10.1007/s10549-010-1027-4. Epub 2010 Jul 13. Breast Cancer Res Treat. 2010. PMID: 20625816
Neoadjuvant pegylated liposomal doxorubicin in combination with cisplatin and infusional fluoruracil (CCF) with and without endocrine therapy in locally advanced primary or recurrent breast cancer.
Torrisi R, Montagna E, Scarano E, Dellapasqua S, Cancello G, Iorfida M, Luini A, Veronesi P, Viale G, Goldhirsch A, Colleoni M. Torrisi R, et al. Among authors: cancello g. Breast. 2011 Feb;20(1):34-8. doi: 10.1016/j.breast.2010.06.005. Epub 2010 Jul 16. Breast. 2011. PMID: 20638282 Free article.
Phase II trial of combination of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil (CCF) plus trastuzumab as preoperative treatment for locally advanced and inflammatory breast cancer.
Torrisi R, Cardillo A, Cancello G, Dellapasqua S, Balduzzi A, Ghisini R, Luini A, Veronesi P, Viale G, Goldhirsch A, Colleoni M. Torrisi R, et al. Among authors: cancello g. Clin Breast Cancer. 2010 Dec 1;10(6):483-8. doi: 10.3816/CBC.2010.n.064. Clin Breast Cancer. 2010. PMID: 21147693 Clinical Trial.
Increased mean corpuscular volume of red blood cells predicts response to metronomic capecitabine and cyclophosphamide in combination with bevacizumab.
Dellapasqua S, Bagnardi V, Bertolini F, Sandri MT, Pastrello D, Cancello G, Montagna E, Balduzzi A, Mancuso P, Luini A, Goldhirsch A, Colleoni M. Dellapasqua S, et al. Among authors: cancello g. Breast. 2012 Jun;21(3):309-13. doi: 10.1016/j.breast.2012.01.015. Epub 2012 Feb 16. Breast. 2012. PMID: 22341133 Free article.
Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activity.
Montagna E, Cancello G, Bagnardi V, Pastrello D, Dellapasqua S, Perri G, Viale G, Veronesi P, Luini A, Intra M, Calleri A, Rampinelli C, Goldhirsch A, Bertolini F, Colleoni M. Montagna E, et al. Among authors: cancello g. Clin Breast Cancer. 2012 Jun;12(3):207-14. doi: 10.1016/j.clbc.2012.03.008. Epub 2012 Apr 20. Clin Breast Cancer. 2012. PMID: 22520733 Clinical Trial.
45 results